First-in-class liver-directed THR-β agonist approved for metabolic-associated steatohepatitis (MASH). Reduces liver fat, fibrosis, and inflammation without systemic thyroid hormone effects.
Selective agonist of thyroid hormone receptor beta in hepatocytes activates metabolic genes; increases fatty acid oxidation, reduces hepatic lipogenesis and inflammation, improves fibrosis. Highly selective for THR-β minimizes cardiac/bone effects.
Selective agonist of thyroid hormone receptor beta in hepatocytes activates metabolic genes; increases fatty acid oxidation, reduces hepatic lipogenesis and inflammation, improves fibrosis. Highly selective for THR-β minimizes cardiac/bone effects.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2026 The Doctors Platform. All Right Reserved.
